Lead Product(s) : FT011
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Certa Therapeutics Receives EU Orphan Designation for FT011 in Systemic Sclerosis
Details : FT011 is a novel, first-in-class oral therapy, that acts as a GPCR inhibitor and receives ODD and Fast Track designation. It is being developed for the treatment of systemic sclerosis (scleroderma).
Product Name : FT011
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : FT011
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYP-001,Prednisone
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Treated in Phase 2 GvHD Trial
Details : CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which is being evaluated for the treatment of acute graft versus host disease.
Product Name : Cymerus MSCs
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : CYP-001,Prednisone
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT011
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Certa Therapeutics' FT011 Granted US FDA Fast Track for Treating Systemic Sclerosis
Details : FT011 is a novel, first-in-class oral therapy, which acts as a GPCR receptor inhibitor. It is being developed for the treatment of systemic sclerosis (scleroderma).
Product Name : FT011
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2024
Lead Product(s) : FT011
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : SPRIM Global Investments
Deal Size : $21.0 million
Deal Type : Financing
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
Details : The net proceeds will be used for the Phase 3 clinical investigation of the company's PRT120 oral therapy for the treatment of patients with peanut allergy.
Product Name : PRT120
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : SPRIM Global Investments
Deal Size : $21.0 million
Deal Type : Financing
Lead Product(s) : FT011
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs advancing through clinical development for scleroderma (systemic sclerosis). It targets GPCR receptor.
Product Name : FT011
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : FT011
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Product Name : IHL-675A
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 26, 2023
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Product Name : IHL-675A
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT011
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT011 has been designed and developed as potent and selective antagonists to the GPCR target, inhibiting anti-fibrotic and anti-inflammatory pathways. Currently is being investigated for scleroderma.
Product Name : FT011
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : FT011
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRT120 is an investigational oral immunotherapy with a novel high dose, rapid escalation dosing regimen for the treatment of peanut allergy. The placebo-controlled trial confirms the effectiveness of PRT120 comprising Prota's rapid escalation dosing regi...
Product Name : PRT120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2022
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PRT120-treated group achieved clinically meaningful improvements in quality of life compared with the placebo group at 12-months post-treatment (p= 0.002).
Product Name : PRT120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : PRT120
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable